CR20240045A - Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer - Google Patents
Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncerInfo
- Publication number
- CR20240045A CR20240045A CR20240045A CR20240045A CR20240045A CR 20240045 A CR20240045 A CR 20240045A CR 20240045 A CR20240045 A CR 20240045A CR 20240045 A CR20240045 A CR 20240045A CR 20240045 A CR20240045 A CR 20240045A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pi3k
- inhibit
- methods
- compounds
- treating cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 102000001708 Protein Isoforms Human genes 0.000 title abstract 2
- 108010029485 Protein Isoforms Proteins 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 title 1
- 108091007960 PI3Ks Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 108030003690 Phosphatidylinositol-4,5-bisphosphate 3-kinases Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta descripción proporciona compuestos de la Fórmula (I) y sales farmacéuticamente aceptables de estos, que inhiben la isoforma alfa (PI3Ka) de la fosfatidilinositol 4,5-bisfosfato 3-quinasa (PI3K). Estas entidades químicas son útiles, por ejemplo, para tratar una afección, enfermedad o trastorno en el que el aumento (por ejemplo, excesivo) de la activación de PI3Ka contribuye a la patología y/o a los síntomas y/o a la progresión de la afección, enfermedad o trastorno (por ejemplo, cáncer) en un sujeto (por ejemplo, un ser humano). Esta descripción también proporciona composiciones que contienen la misma, así como también métodos de uso y fabricación de la misma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231156P | 2021-08-09 | 2021-08-09 | |
| PCT/US2022/039674 WO2023018636A1 (en) | 2021-08-09 | 2022-08-08 | Compounds that inhibit pi3k isoform alpha and methods for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20240045A true CR20240045A (es) | 2024-02-20 |
Family
ID=83188497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20240045A CR20240045A (es) | 2021-08-09 | 2022-08-08 | Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240343728A1 (es) |
| EP (1) | EP4363414A1 (es) |
| JP (1) | JP2024533975A (es) |
| KR (1) | KR20240051953A (es) |
| CN (1) | CN118159534A (es) |
| AU (1) | AU2022325819A1 (es) |
| CA (1) | CA3227902A1 (es) |
| CL (1) | CL2024000327A1 (es) |
| CO (1) | CO2024000448A2 (es) |
| CR (1) | CR20240045A (es) |
| DO (1) | DOP2024000019A (es) |
| EC (1) | ECSP24008488A (es) |
| IL (1) | IL310588A (es) |
| MA (1) | MA63885B1 (es) |
| MX (1) | MX2024000708A (es) |
| PE (1) | PE20240652A1 (es) |
| WO (1) | WO2023018636A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024097721A1 (en) | 2022-11-02 | 2024-05-10 | Petra Pharma Corporation | Targeting allosteric and orthosteric pockets of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
| WO2024233256A1 (en) | 2023-05-05 | 2024-11-14 | Eli Lilly And Company | Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer |
| WO2025036439A1 (en) * | 2023-08-16 | 2025-02-20 | Laekna Pharmaceutical Ningbo Co., Ltd. | Multicyclic compounds and their use as pi3k alpha inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2408773A2 (en) * | 2009-03-20 | 2012-01-25 | Amgen, Inc | Inhibitors of pi3 kinase |
| DE102009043260A1 (de) * | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate |
| BR112017000132A2 (pt) * | 2014-07-04 | 2018-01-09 | Lupin Ltd | composto, composição farmacêutica e método de tratamento ou prevenção de uma doença responsiva à inibição da atividade de pi3k |
| TWI601732B (zh) * | 2015-07-02 | 2017-10-11 | 赫孚孟拉羅股份公司 | 苯并氧氮呯噁唑啶酮化合物及其用途 |
| WO2017221272A1 (en) * | 2016-06-23 | 2017-12-28 | Sun Pharmaceutical Industries Limited | Process for the preparation of idelalisib |
| WO2021001431A1 (en) * | 2019-07-02 | 2021-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer |
-
2022
- 2022-08-08 CN CN202280062281.6A patent/CN118159534A/zh active Pending
- 2022-08-08 CA CA3227902A patent/CA3227902A1/en active Pending
- 2022-08-08 WO PCT/US2022/039674 patent/WO2023018636A1/en active Application Filing
- 2022-08-08 KR KR1020247007455A patent/KR20240051953A/ko active Pending
- 2022-08-08 JP JP2024506896A patent/JP2024533975A/ja active Pending
- 2022-08-08 MA MA63885A patent/MA63885B1/fr unknown
- 2022-08-08 IL IL310588A patent/IL310588A/en unknown
- 2022-08-08 EP EP22764505.8A patent/EP4363414A1/en active Pending
- 2022-08-08 AU AU2022325819A patent/AU2022325819A1/en active Pending
- 2022-08-08 CR CR20240045A patent/CR20240045A/es unknown
- 2022-08-08 MX MX2024000708A patent/MX2024000708A/es unknown
- 2022-08-08 PE PE2024000156A patent/PE20240652A1/es unknown
- 2022-08-08 US US18/293,823 patent/US20240343728A1/en active Pending
-
2024
- 2024-01-18 CO CONC2024/0000448A patent/CO2024000448A2/es unknown
- 2024-02-01 EC ECSENADI20248488A patent/ECSP24008488A/es unknown
- 2024-02-02 CL CL2024000327A patent/CL2024000327A1/es unknown
- 2024-02-02 DO DO2024000019A patent/DOP2024000019A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2024000448A2 (es) | 2024-02-15 |
| JP2024533975A (ja) | 2024-09-18 |
| CA3227902A1 (en) | 2023-02-16 |
| IL310588A (en) | 2024-04-01 |
| CL2024000327A1 (es) | 2024-08-09 |
| WO2023018636A1 (en) | 2023-02-16 |
| CN118159534A (zh) | 2024-06-07 |
| AU2022325819A1 (en) | 2024-02-29 |
| PE20240652A1 (es) | 2024-04-04 |
| MA63885A1 (fr) | 2024-09-30 |
| EP4363414A1 (en) | 2024-05-08 |
| MA63885B1 (fr) | 2025-01-31 |
| ECSP24008488A (es) | 2024-05-31 |
| MX2024000708A (es) | 2024-02-08 |
| DOP2024000019A (es) | 2024-03-15 |
| KR20240051953A (ko) | 2024-04-22 |
| US20240343728A1 (en) | 2024-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000271A (es) | Derivados de la urea que pueden ser utilizados para tratar el cáncer | |
| DOP2024000019A (es) | Compuestos que inhiben la isoforma alfa de pi3k y métodos para tratar el cáncer | |
| ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
| CO2019008932A2 (es) | Imidazo-quinolinas sustituidas como moduladores de nlrp3 | |
| DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| UY38742A (es) | Compuestos de 2,3,5-pyrazolo[1,5-a]pirimidina trisustituida | |
| CL2019001079A1 (es) | Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina. | |
| GT200500325A (es) | Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa | |
| CL2022002919A1 (es) | Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune | |
| UY29093A1 (es) | Derivados de 4-oxo-3. 4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones que los contienen, procesos de preparación y aplicaiones. | |
| MX2013002713A (es) | Imidazopiridazinas sustituidas. | |
| UY30094A1 (es) | Compuestos químicos | |
| CO2023010023A2 (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| CL2021003568A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina (divisional de solicitud n° 202101198) | |
| CL2020001107A1 (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3. | |
| AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
| ES2164899T3 (es) | Uso de alcaloides de la clase lamellarina en metodos de tratamiento. | |
| UY39061A (es) | Inhibidores macrocíclicos de rip2-cinasa | |
| UY39819A (es) | Métodos para tratar el cáncer | |
| MX2018008157A (es) | Alfa-amino esteres de derivado de hidroxipropiltiazolidin carboxamida, y formas de sales y polimorfos cristalinos de estos. | |
| AR126147A1 (es) | Derivados de urea para tratar el cáncer | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| UY31812A (es) | Derivados de cinolina como inhibidores de csf-1 | |
| DOP2022000203A (es) | 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad antagonista gpr52 | |
| CR20240216A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |